SC
CORT icon

Savant Capital’s Corcept Therapeutics CORT Stock Holding History

Savant Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$605K Sell
6,935
-315
-4% -$19K ﹤0.01% 1128
2026
Q1 		$292K Buy
7,250
+1,200
+20% +$44.9K ﹤0.01% 1191
2025
Q4 		$211K Sell
6,050
-395
-6% -$31K ﹤0.01% 1267
2025
Q3 		$536K Buy
6,445
+420
+7% +$30.4K ﹤0.01% 771
2025
Q2 		$442K Sell
6,025
-3
-0% -$218 ﹤0.01% 788
2025
Q1 		$689K Sell
6,028
-12,361
-67% -$752K 0.01% 583
2024
Q4 		$927K Buy
18,389
+21
+0.1% +$1.1K 0.01% 681
2024
Q3 		$850K Buy
18,368
+43
+0.2% +$1.53K 0.01% 702
2024
Q2 		$595K Buy
18,325
+5,602
+44% +$153K 0.01% 732
2024
Q1 		$320K Buy
+12,723
New +$301K ﹤0.01% 880

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Savant Capital's CORT Position: Q2 2026 in Review

Savant Capital reduced its Corcept Therapeutics (CORT) stake by 4.3% in Q2 2026, selling an estimated $19K and leaving 6,935 shares worth $605K. The position accounts for ﹤0.01% of the portfolio, ranked #1128.

Savant Capital first reported a position in CORT in Q1 2024 and has held it in 10 quarters since. The position peaked at $927K in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Savant Capital held 6,935 shares of Corcept Therapeutics worth $605K as of Q2 2026.
  • Savant Capital sold 315 Corcept Therapeutics shares in Q2 2026, an estimated $19K.
  • Corcept Therapeutics made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1128 holding.
  • Savant Capital first reported a position in Corcept Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Savant Capital's Corcept Therapeutics position peaked at $927K in Q4 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.